Skip Navigation

American Journal of Epidemiology 2005 161(6):595-603; doi:10.1093/aje/kwi065
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kpozèhouen, A.
Right arrow Articles by Salamon, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kpozèhouen, A.
Right arrow Articles by Salamon, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Copyright © 2005 by the Johns Hopkins Bloomberg School of Public Health All rights reserved

SPECIAL ARTICLE

Use of a Bayesian Approach to Decide When to Stop a Therapeutic Trial: The Case of a Chemoprophylaxis Trial in Human Immunodeficiency Virus Infection

Alphonse Kpozèhouen1, Ahmadou Alioum2, Xavier Anglaret1, Philippe Van de Perre3, Geneviève Chêne1 and Roger Salamon1

1 INSERM U 593, Université Victor Segalen Bordeaux 2, France
2 INSERM E 0338, Université Victor Segalen Bordeaux 2, France
3 Regional Hospital Center, Laboratory of Bacteriology-Virology, Montpellier, France

Correspondence to Dr. Alphonse Kpozèhouen, INSERM U 593, Université Victor Segalen Bordeaux 2, 146, rue Léo-Saignat, 33076 Bordeaux Cedex, France (e-mail: Alphonse.Kpozehouen{at}isped.u-bordeaux2.fr).

From 1996 to 1998, a phase III, placebo-controlled, therapeutic trial was conducted in Abidjan, Ivory Coast, to assess the efficacy of cotrimoxazole prophylaxis in reducing severe morbidity in adults at early stages of human immunodeficiency virus infection. The authors used the real data from this trial to simulate three Bayesian interim analyses. Three prior distributions were considered: a noninformative one, a skeptical one, and one based on external information. The posterior distribution was calculated by using directed acyclic graphs and Gibbs sampling. This Bayesian approach showed different results according to the prior distribution chosen. Although use of the noninformative prior would have led to stopping the trial at the same time that the frequentist approach would have, the skeptical prior would have led to continuing it, and the prior based on external data would have led to stopping it 1 year earlier.

Bayesian approach; cotrimoxazole; counting process; Cox model; directed acyclic graph; Gibbs sampling

Abbreviations: ANRS   Agence Nationale de Recherche sur le Sida; CI   Côte d'Ivoire; HIV   human immunodeficiency virus


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J EpidemiolHome page
P. A. H. van Noord and I. van der Tweel
RE: "USE OF A BAYESIAN APPROACH TO DECIDE WHEN TO STOP A THERAPEUTIC TRIAL: THE CASE OF A CHEMOPROPHYLAXIS TRIAL IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION"
Am. J. Epidemiol., November 15, 2005; 162(10): 1033 - 1035.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.